Abstract
Our laboratory has been testing the hypothesis that genetic modulation of the β-adrenergic signaling cascade can enhance cardiac function. We have previously shown that transgenic mice with cardiac overexpression of either the human β2-adrenergic receptor (β2AR) or an inhibitor of the β- adrenergic receptor kinase (βARK), an enzyme that phosphorylates and uncouples agonist-bound receptors, have increased myocardial inotropy. We now have created recombinant adenoviruses encoding either the β2AR (Adeno- β2AR) or a peptide βARK inhibitor (consisting of the carboxyl terminus of βARK1, Adeno-βARKct) and tested their ability to potentiate β-adrenergic signaling in cultured adult rabbit ventricular myocytes. As assessed by radioligand binding, Adeno-β2AR infection led to ~20-fold over-expression of β-adrenergic receptors. Protein immunoblots demonstrated the presence of the Adeno-βARKct transgene. Both transgenes significantly increased isoproterenol-stimulated cAMP as compared to myocytes infected with an adenovirus encoding β-galactosidase (Adeno-βGal) but did not affect the sarcolemmal adenylyl cyclase response to Forskolin or NaF. β-Adrenergic agonist-induced desensitization was significantly inhibited in Adeno-βARKct- infected myocytes (16±2%) as compared to Adeno-βGal-infected myocytes (37±1%, P < 0.001). We conclude that recombinant adenoviral gene transfer of the β2AR or an inhibitor of βARK-mediated desensitization can potentiate β-adrenergic signaling.
Original language | English (US) |
---|---|
Pages (from-to) | 288-296 |
Number of pages | 9 |
Journal | Journal of Clinical Investigation |
Volume | 99 |
Issue number | 2 |
DOIs | |
State | Published - Jan 15 1997 |
Keywords
- congestive heart failure
- cultured cells
- gene therapy
- myocardium
- β-adrenergic receptor
ASJC Scopus subject areas
- Medicine(all)